Addex Pharmaceuticals Ltd of Switzerland has been awarded a $900,000 grant from the Michael J. Fox Foundation in the US to help fund a Phase 2 study of its candidate treatment for Parkinson’s disease levodopa-induced dyskinesia, ADX48621.
Forbion Capital Partners has raised €190 million for investment in the life sciences in what the managing partner described as conditions that have never been more challenging.
The Roche Group has announced plans to invest $25 million upfront for access to new peptide technology that locks peptides into their biologically active shape, mimicking the structures found in nature.
Genzyme Corp has rejected an unsolicited cash takeover bid from Sanofi-Aventis which values the company at $69 per share or $18.5 billion. The rejection was communicated in a letter to the Sanofi CEO Christopher Viehbacher.
A new company has been set up in the Benelux to discover and develop small molecule drugs for treating bone and joint diseases. It combines assets from TiGenix NV of Belgium and Therosteon BV of the Netherlands.
Cancer Research Technology of the UK has signed an agreement with Bayer Schering Pharma AG to evaluate new leptin antagonist peptides as potential treatments for gynaecological diseases, including cancer.
The Roche Group has announced plans to acquire privately-owned BioImagene Inc of Sunnyvale, California for $100 million in order to bolster its position as a provider of personalised medicines. BioImagene develops digital pathology services.
Building on momentum in the first-half year, SkyePharma Plc said it expects to report an increase in revenue for 2010. Driving the business forward will be the new CEO, Axel Müller, who takes over the top job from Ken Cunningham on 23 August.
Active Biotech AB, a listed Swedish drug development company focused on manipulating the immune system to treat major diseases, said its net loss for the first half of 2010 narrowed to SEK 108.1 million from SEK 118.6 million a year earlier.
Wilex AG has announced the successful completion of a rights issue which has raised €10 million in new money. The proceeds will be used to finance the ongoing clinical development of the company’s oncology portfolio.